MedTrace Logo

Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease

NCT01324518 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-04-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether ORM-12741 is safe and effective in the treatment of Alzheimer's disease.

Conditions

Interventions

DRUG

ORM-12741

60mg twice a day

DRUG

ORM-12741

200mg twice a day

DRUG

Placebo for ORM-12741

Placebo twice a day

Sponsors & Collaborators

  • Orion Corporation, Orion Pharma

    lead INDUSTRY

Principal Investigators

  • Juha Rinne, Prof · Clinical Research services Turku (CRST)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-09-30
Completion
2012-10-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01324518 on ClinicalTrials.gov